Colin Hislop
Chief Tech/Sci/R&D Officer bei EIGER BIOPHARMACEUTICALS, INC.
Profil
Colin Hislop is currently the Senior VP-Clinical & Development Operations at Eiger BioPharmaceuticals, Inc. He previously worked as a Principal at Eli Lilly & Co. and as a Manager-Clinical Development at Procter & Gamble Co. He also held Vice President-Clinical Development positions at CV Therapeutics, Inc. and Peninsula Pharmaceuticals, Inc. from 2001 to 2005.
From 2005 to 2016, he served as the Chief Medical Officer & Senior Vice President at Anthera Pharmaceuticals, Inc. He was also the Chief Development Officer at Versartis, Inc. in 2017.
Dr. Hislop holds a doctorate from the University of London and an undergraduate degree from the University of Surrey.
Aktive Positionen von Colin Hislop
| Unternehmen | Position | Beginn |
|---|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Ehemalige bekannte Positionen von Colin Hislop
| Unternehmen | Position | Ende |
|---|---|---|
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Chief Tech/Sci/R&D Officer | 05.09.2017 |
| ANTHERA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.04.2016 |
Peninsula Pharmaceuticals, Inc.
 Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Chief Tech/Sci/R&D Officer | 01.06.2005 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Chief Tech/Sci/R&D Officer | 01.09.2004 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Ausbildung von Colin Hislop
| University of London | Doctorate Degree |
| University of Surrey | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| ANTHERA PHARMACEUTICALS, INC. | Health Technology |
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Commercial Services |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
